RxDoctor Payments Data

Kenneth Johnson, MD

Psychiatry · Milwaukee, WINPI 1124059316

Payments from drug & device makers

$1,551in general payments, 2019–2025

Across 81 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$608
  • Otsuka America Pharmaceutical, Inc.$468
  • Johnson & Johnson$307
  • AbbVie$54
  • Vanda Pharmaceuticals Inc.$44
  • Teva Pharmaceuticals USA, Inc.$36
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$1,551100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,551 in reported general payments places this provider in the 85th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$32,615
Medicare patients
158
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl173$282,204
AustedoDeutetrabenazine36$224,943
Invega SustennaPaliperidone Palmitate19$55,114
Aripiprazole580$25,104
AuvelityDextromethorphan Hbr/Bupropion16$17,284
TrintellixVortioxetine Hydrobromide28$17,192
Lisdexamfetamine Dimesylate46$10,762
Buspirone Hcl638$10,462
VyvanseLisdexamfetamine Dimesylate27$10,294
Quetiapine Fumarate499$10,041
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine265$9,353
Bupropion XlBupropion Hcl390$9,191
Ambien CrZolpidem Tartrate13$8,431
Duloxetine Hcl362$7,217
Lamotrigine347$6,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Savella$54$287,478184 claims
Teva Pharmaceuticals USA, Inc.Austedo$36$224,94336 claims
Johnson & JohnsonInvega Sustenna$307$55,11419 claims
Axsome Therapeutics, Inc.Auvelity$608$17,28416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →